Common Health Concerns:

• ➤ Simplify treatment regimens
  
• ➤ Improve patient adherence
  
• ➤ Minimize the risk of hypoglycaemia and other complications

Safety, tolerability and clinical utility are at the core of our product development strategy.


Product Highlights:




• ➤ Vogli Rapid (Voglibose + Repaglinide): A fast-acting combination design to tackle post-meal glucose spikes, especially relevant for Indian carbohydrate-rich diets. It is India’s first fixed-dose combination in this class and the No.1 formulation for postprandial blood glucose (PPBG) control.
  
• ➤ Vogli GM (Voglibose + Glimepiride + Metformin): A triple drug formulation that targets insulin resistance, enhances insulin secretion and delays carbohydrate absorption.
  
• ➤ Dapanova (Dapagliflozin and its combinations): Offering glycaemic control along with cardiorenal protection. Its combinations are developed to meet the diverse and advanced needs of Indian diabetic patients. A unique patient centric: Sugar Kumar is integrated for bridging the current gap of practicing clinicians & patients on diabetes counselling (education & awareness)

Why Choose Medley’s Glycekare?


• ➤ Manufactured in WHO-GMP certified facilities with stringent quality control protocols.
  
• ➤ Backed by scientific rationale and real-world relevance
  
• ➤ Medley ensures accessible, dependable care across all stages of diabetes management.



Connect with Glycekare:


For more information, clinical support, or to explore our full portfolio of diabetes therapies, connect with the Glycekare team.

We are committed to empowering clinicians and enhancing patient outcomes in everyday practice.




Anti Diabetic

Trigem 1


Description
Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.

Indications
Type II diabetes mellitus uncontrolled by any dual drug therapy.
Composition
Each tablet contains:
 


Glimepiride
1 mg


Pioglitazone
15 mg


Metformin SR
500 mg


Dosage
One tablet once daily.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Trigem 1 is available as a strip of 10 tablets.
Trigem 2


Description
Type 2 diabetes mellitus is a progressive disorder, and although oral dual therapy is often initially successful, it is associated with a secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia. Later in the course of the disease, the use of combinations of three oral agents may delay the need for insulin while maintaining glycemic control, thus making aggressive oral treatment more acceptable for many patients.

Combination therapy using oral antidiabetic agents with different mechanisms of action can be highly effective in achieving and maintaining target blood glucose levels.

Indications
Type II diabetes mellitus uncontrolled by any dual drug therapy.
Composition
Each tablet contains:
 


Glimepiride
2 mg


Pioglitazone
15 mg


Metformin SR
500 mg


Dosage
One tablet once daily.
Side Effects
Headache, flu like syndrome, nausea, sinusitis and rarely hypoglycemia may occur.
Contraindications
Known hypersensitivity to any of the components.
Presentation
Trigem 2 is available as a strip of 10 tablets.
Vogli 0.2


Description
It is an alpha-glycosidase inhibitor. It inhibits the conversion of disaccharides into monosaccharide like glucose (Absorbable form), thereby delaying the digestion and absorption of carbohydrates resulting in decreased postprandial hyperglycemia. It is important to control post-challenge hyperglycemia tended to be more strongly related to insulin resistance, higher blood pressure, obesity, and dyslipidemia.
Indications
• Non-insulin-dependent diabetes mellitus.
• In insulin dependent diabetes mellitus.
• Voglibose may also be used in combination with a sulfonylurea when diet plus either voglibose or a sulfonylurea alone do not result in adequate glycemic control.
Composition
Each tablet contains:
 


Voglibose
0.2 mg


Dosage
Dosage must be individualized; not exceeding the maximum recommended dosage of 0.6mg 3 times daily. Voglibose should be taken three times daily at the start (with the first bite) of each main meal.
Side Effects
Gastrointestinal side effects like abdominal pain, diarrhea, and flatulence can occur.
Precautions
Since voglibose is not metabolized and eliminated unchanged by the kidneys, it should not be used in renal failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli 0.3


Description
It is an alpha-glycosidase inhibitor. It inhibits the conversion of disaccharides into monosaccharide like glucose (Absorbable form), thereby delaying the digestion and absorption of carbohydrates resulting in decreased postprandial hyperglycemia. It is important to control post-challenge hyperglycemia tended to be more strongly related to insulin resistance, higher blood pressure, obesity, and dyslipidemia.
Indications
• Non-insulin-dependent diabetes mellitus.
• In insulin dependent diabetes mellitus.
• Voglibose may also be used in combination with a sulfonylurea when diet plus either voglibose or a sulfonylurea alone do not result in adequate glycemic control.
Composition
Each tablet contains:
 


Voglibose
0.3 mg


Dosage
Dosage must be individualized; not exceeding the maximum recommended dosage of 0.6mg 3 times daily. Voglibose should be taken three times daily at the start (with the first bite) of each main meal.
Side Effects
Gastrointestinal side effects like abdominal pain, diarrhea, and flatulence can occur.
Precautions
Since voglibose is not metabolized and eliminated unchanged by the kidneys, it should not be used in renal failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 1


Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 


Glimepiride
1 mg


Metformin (Sustained Release)
500 mg


Voglibose
0.2 mg


Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 2


Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 


Glimepiride
2 mg


Metformin (Sustained Release)
500 mg


Voglibose
0.2 mg


Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli M 0.2


Description
Postprandial hyperglycemia is an independent risk factor for macro vascular complications. However, the normalization of postprandial plasma glucose peaks in clinical practice is recognized as more problematic than the overall management of fasting plasma glucose levels. The causes of PPHG are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver, peripheral insulin resistance. Voglibose in Vogli M reduces postprandial hyperglycemia primarily by interfering with the carbohydrate digesting enzymes and delaying glucose absorption. Metformin in Vogli M reduces Insulin Resistance, decreases glucose absorption & inhibits Gluconeogenesis. Both drug acts on different parameters and gives additive effect in the management of Post Prandial Hyperglycemia and achieves A1C goal.
Indications
• Post Prandial Hyperglycemia
• Type 2 diabetes not controlled with diet/ monotherapy
• Obese Type-2-Diabetic Patients
• Impaired Glucose Tolerance (IGT)
• Adjuvant to Insulin therapy in Type-1 Diabetic.
Composition
Each tablet contains:
 


Voglibose
0.2 mg


Metformin
500 mg


Dosage
1 tablet with each major meal
Side Effects
Metallic taste, abdominal distension, Nausea, Vomiting, Diarrhoea.
Contraindication
Pregnancy, Liver disease, Kidney failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli M 0.3


Description
Postprandial hyperglycemia is an independent risk factor for macro vascular complications. However, the normalization of postprandial plasma glucose peaks in clinical practice is recognized as more problematic than the overall management of fasting plasma glucose levels. The causes of PPHG are influenced by many factors which include a rapid flux of glucose from the gut, impaired insulin release, endogenous glucose production by the liver, peripheral insulin resistance. Voglibose in Vogli M reduces postprandial hyperglycemia primarily by interfering with the carbohydrate digesting enzymes and delaying glucose absorption. Metformin in Vogli M reduces Insulin Resistance, decreases glucose absorption & inhibits Gluconeogenesis. Both drug acts on different parameters and gives additive effect in the management of Post Prandial Hyperglycemia and achieves A1C goal.
Indications
• Post Prandial Hyperglycemia
• Type 2 diabetes not controlled with diet/ monotherapy
• Obese Type-2-Diabetic Patients
• Impaired Glucose Tolerance (IGT)
• Adjuvant to Insulin therapy in Type-1 Diabetic.
Composition
Each tablet contains:
 


Voglibose
0.3 mg


Metformin
500 mg


Dosage
1 tablet with each major meal
Side Effects
Metallic taste, abdominal distension, Nausea, Vomiting, Diarrhoea.
Contraindication
Pregnancy, Liver disease, Kidney failure.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 1 Forte


Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 


Glimepiride
1 mg


Metformin (Sustained Release)
500 mg


Voglibose
0.3 mg


Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Vogli GM 2 Forte


Description
Type 2 diabetes is one of the major problems confronting the health care system. Currently 25 million Indians have diabetes and the projections indicate Indians would be the largest group by the year 2025 AD. It is the leading cause of blindness and end-stage renal disease, and it is a major risk factor for cardiovascular disease. Increased glycated haemoglobin (HbA1c) is associated with an increased risk of myocardial infarction. Glycated haemoglobin levels reflect fasting and postprandial glycaemia. Fasting hyperglycaemia is represented as an elevated hepatic glucose output and/or defect in early insulin secretion.
Indications
Type 2 diabetes not controlled with dual therapy
Obese Type-2-Diabetic Patients
Composition
Each Tablet consists:
 


Glimepiride
2 mg


Metformin (Sustained Release)
500 mg


Voglibose
0.3 mg


Dosage
One tablet twice daily.
Presentation
Vogli is available as a strip of 10 tablets.
Glytrin

Indications
• Type II Diabetes
Composition
Each Tablet consists:
 


Teneligliptin
20 mg


Presentation
Glytrin is available as a strip of 10 tablets.
Glytrin Met

Indications
• Type II Diabetes
Composition
Each Tablet consists:
 


Teneligliptin
20 mg


Metformin (ER)
500 mg


Presentation
Glytrin Met is available as a strip of 10 tablets.